Let’s Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia

Background: Therapy for acute lymphoblastic leukemia (ALL) are currently initially efficient, but even if a high percentage of patients have an initial complete remission (CR), most of them relapse. Recent data shows that immunotherapy with either bispecific T-cell engagers (BiTEs) of chimeric antig...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Dalma Deak, Cristina Pop, Alina-Andreea Zimta, Ancuta Jurj, Alexandra Ghiaur, Sergiu Pasca, Patric Teodorescu, Angela Dascalescu, Ion Antohe, Bogdan Ionescu, Catalin Constantinescu, Anca Onaciu, Raluca Munteanu, Ioana Berindan-Neagoe, Bobe Petrushev, Cristina Turcas, Sabina Iluta, Cristina Selicean, Mihnea Zdrenghea, Alina Tanase, Catalin Danaila, Anca Colita, Andrei Colita, Delia Dima, Daniel Coriu, Hermann Einsele, Ciprian Tomuleasa
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2019-12-01
Colecção:Frontiers in Immunology
Assuntos:
blinatumoman
acute lymphoblastic leukemia
bridge-to-transplant
real life setting
bispecific antobodies
Acesso em linha:https://www.frontiersin.org/article/10.3389/fimmu.2019.02856/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados